Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00141297 · ClinicalTrials.gov registry record · Phase 1
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
A Phase 1 study of Neoplasms and Lymphoma, Non-Hodgkin, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
- 4
- Study locations
NCT00141297 is a Phase 1 study of Neoplasms and Lymphoma, Non-Hodgkin that has completed, run by Pfizer. The registered enrollment target is 74 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT00141297, a Phase 1 study of Neoplasms and Lymphoma, Non-Hodgkin, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
- 4
- Study locations
Study Summary
PD-0332991 may work in cancer by stopping cancer cells from multiplying. PD-0332991 is in a new class of drugs called cyclin-dependent kinase (CDK inhibitors). This research study is the first time that PD-0332991 will be given to people. PD-0332991 is taken by mouth daily.
Conditions Studied
Interventions
- DRUG PD-0332991
Study Locations (4)
Pennsylvania
- Abramson Cancer Center Hospital of the University of Pennsylvania - Philadelphia
- Pharmacy/PCAM/West Pavillion - Philadelphia
Michigan
- Karmanos Cancer Institute - Detroit
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2004-09 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00141297
The ClinicalTrials.gov registry entry for NCT00141297 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (95% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which PD-0332991 is the first listed.
NCT00141297 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Pennsylvania, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT00141297 about?
NCT00141297 is a clinical study titled "A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer". PD-0332991 may work in cancer by stopping cancer cells from multiplying. PD-0332991 is in a new class of drugs called cyclin-dependent kinase (CDK inhibitors). This research study is the first time that PD-0332991 will be given to people. PD-0332991 is taken by mouth daily.
What is the current status of trial NCT00141297?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2004-09. Estimated completion is 2014-12.
What conditions does trial NCT00141297 study?
This clinical trial studies the following conditions: Neoplasms, Lymphoma, Non-Hodgkin.
What interventions are being tested in trial NCT00141297?
The interventions under investigation include: PD-0332991 (DRUG).
Who is sponsoring clinical trial NCT00141297?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00141297 being conducted?
This trial has 4 study locations across Michigan, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.